Ce post provient d'un groupe suggéré
Global NASH Biomarker Market By End User: Hospitals, Diagnostic Centers, and Research Institutions
The global NASH (Non-Alcoholic Steatohepatitis) biomarker market by end user is witnessing significant growth due to rising prevalence of metabolic disorders, obesity, diabetes, and liver-related diseases worldwide. Biomarkers are crucial for early detection, monitoring disease progression, and evaluating treatment efficacy in NASH patients, supporting better clinical outcomes.
The market is segmented by end users into hospitals, diagnostic centers, and research institutions. Hospitals are the primary end users, leveraging biomarkers for patient diagnosis, disease monitoring, and management. Advanced hospitals integrate imaging, blood-based, and molecular biomarkers to provide comprehensive liver disease assessments, particularly for high-risk patients.
Diagnostic centers are expanding their adoption of NASH biomarkers to provide specialized testing services, including blood tests, imaging evaluations, and molecular assays. These centers support outpatient care and serve as referral points for hospitals.
Research institutions are driving innovation in biomarker discovery, validation, and clinical application. They play a key role in developing new diagnostic tools,…


